Amino Acids

, 36:709

Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer

Review Article

Abstract

Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest cancers world-wide with an estimated annual incidence and mortality rates of approximately 6,500 cases in the UK, over 40,000 cases in Europe, 19,000 cases in Japan and over 30,000 cases in the United States. Difficulty to diagnose the disease at an early stage, rapid progression and intrinsic resistance to currently available therapies are major factors that contribute to poor disease outcome in these patients (overall 5 years survival, <3%). Identification of cancer cell-encoded genes that contribute to the development of intrinsic resistance and metastatic spread of the PDA tumors, may yield immediate clinical benefits in terms of revealing new therapeutic targets for effective treatment of the disease. This article discusses the significance of tissue-type transglutaminase (TG2) whose expression is elevated in the majority of PDA tumors and cell lines. Based on the published data and the results discussed in this review, TG2 appears to be a promising target for containment and treatment of this formidable disease.

Keywords

Chemoresistance Metastasis Invasion Autophagy NF-κB FAK PTEN 

References

  1. Aeschlimann D, Thomazy V (2000) Protein crosslinking in assembly and remodeling of extracellular matrices: the role of transglutaminase. Connect Tissue Res 41:1–27PubMedCrossRefGoogle Scholar
  2. Akar U, Ozpolat B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G (2007) Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5:241–249PubMedCrossRefGoogle Scholar
  3. Akimov SS, Belkin AM (2001) Cell-surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98:1567–1576PubMedCrossRefGoogle Scholar
  4. Akimov SS, Krylov D, Fleishmann LF, Belkin AM (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148:825–838PubMedCrossRefGoogle Scholar
  5. Antonyak MA, Singh US, Lee DA, Boehm JE, Combs C, Zgola MM, Page RL, Cerione RA (2001) Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J Biol Chem 276:33582–33587PubMedCrossRefGoogle Scholar
  6. Antonyak MA, Miller AM, Jansen JM et al (2004) Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 279:41461–41467PubMedCrossRefGoogle Scholar
  7. Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV, Hamstreet JP (2000) Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 89:412–423PubMedCrossRefGoogle Scholar
  8. Brown EJ, Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11:130–135PubMedCrossRefGoogle Scholar
  9. Datta S, Antonayak MA, Cerione RA (2006) Importance of calcium-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry 45:13163–13174PubMedCrossRefGoogle Scholar
  10. Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20:203–213PubMedCrossRefGoogle Scholar
  11. Fesus L, Madi A, Balajthy Z, Nemes Z, Szondy Z (1996) Transglutaminase induction by various cell death and apoptosis pathways. Experientia 52:942–949PubMedCrossRefGoogle Scholar
  12. Fok J, Ekmekcioglu S, Mehta K (2006) Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5:1493–1503PubMedCrossRefGoogle Scholar
  13. Gray MJ, Buren GV, Dallas NA et al (2008) Therapeutic targeting of neurophilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100:109–120PubMedCrossRefGoogle Scholar
  14. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature’s biological glue. Biochem J 368:377–396PubMedCrossRefGoogle Scholar
  15. Guan JL (1997) Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol 29:1086–1096CrossRefGoogle Scholar
  16. Halder J, Kamat AA, Landen CN Jr et al (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12:4916–4924PubMedCrossRefGoogle Scholar
  17. Hasegawa G, Suwa M, Ichikawa Y et al (2003) A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373:793–803PubMedCrossRefGoogle Scholar
  18. Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049–3058PubMedCrossRefGoogle Scholar
  19. Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614–8622PubMedGoogle Scholar
  20. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  21. Jiang D, Ying W, Lu Y, Wan J, Zhai Y, Liu W, Zhu Y, Qiu Z, Qian X, He F (2003) Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 3:724–737PubMedCrossRefGoogle Scholar
  22. Jones RA, Kotsakis P, Johnson TS, Chau DY, Ali S, Melino G, Griffin M (2006) Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 13:1442–1453PubMedCrossRefGoogle Scholar
  23. Joshi S, Guleria R, Pan J, DiPette D, Singh US (2006) Retinoic acid receptors and tissue tansglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25:240–247PubMedGoogle Scholar
  24. Karin MY, Cao YF, Greten FZ, Li Z (2002) NF-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301–310PubMedCrossRefGoogle Scholar
  25. Khera V, Mehta K (1989) Transglutaminase levels and immunologic functions of BCG-elicited mouse peritoneal macrophages isolated by centrifugal elutriation. J Leukoc Biol 45:434–443PubMedGoogle Scholar
  26. Kim DS, Park SS, Nam BH, Kim IH, Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66:10936–10943PubMedCrossRefGoogle Scholar
  27. Klionsky DJ (2007) Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8:931–937PubMedCrossRefGoogle Scholar
  28. Lai TS, Slaughter TF, Peoples KA, Hettqasch JM, Greenberg CS (1998) Regulation of human tissue transglutaminase function by magnesium nucleotide complexes. J Biol Chem 273:1776–1781PubMedCrossRefGoogle Scholar
  29. Landen CN Jr, Chavez-Reyes A, Bucana C et al (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910–6918PubMedCrossRefGoogle Scholar
  30. Laurenzi VD, Melino G (2001) Gene disruption of tissue transglutaminase. Mol Cell Biol 21:148–155PubMedCrossRefGoogle Scholar
  31. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY (2004) Transglutaminase 2 induces nuclear factor-kB activation via a novel pathway in BV-2 microglia. J Biol Chem 279:53725–53735PubMedCrossRefGoogle Scholar
  32. Levine B (2007) Autophagy and cnacer. Nature 446:745–747PubMedCrossRefGoogle Scholar
  33. Lorand L, Graham R (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4:140–156PubMedCrossRefGoogle Scholar
  34. Maheshwari V, Moser AJ (2005) Current management of locally advanced pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 2:356–364PubMedCrossRefGoogle Scholar
  35. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459–2470PubMedCrossRefGoogle Scholar
  36. Mann AP, Verma A, Sethi G et al (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappa B in cancer cells: delineation of a novel pathway. Cancer Res 66:8788–8795PubMedCrossRefGoogle Scholar
  37. McLean GW, Avizienyte E, Frame MC (2003) Focal adhesion kinase as a potential target in oncology. Expert Opin Pharmacother 4:227–234PubMedCrossRefGoogle Scholar
  38. Mehta K (1994) High levels of tissue transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer 58:400–506PubMedCrossRefGoogle Scholar
  39. Mehta K (2005) Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 38:1–18PubMedCrossRefGoogle Scholar
  40. Mehta K, Fok J, Miller FR, Koul D, Sahin AA (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10:8068–8076PubMedCrossRefGoogle Scholar
  41. Mehta K, Fok JY, Mangala LS (2006) Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci 11:173–185PubMedCrossRefGoogle Scholar
  42. Merritt WM, Lin YG, Spannuth WA et al (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated siRNA on ovarian cancer growth. J Natl cancer Inst 100:359–372PubMedCrossRefGoogle Scholar
  43. Mhaouty-Kodija S (2004) Ghα/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 96:363–367CrossRefGoogle Scholar
  44. Mishra S, Murphy LJ (2004) Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279:23863–23868PubMedCrossRefGoogle Scholar
  45. Mohan K, Pinto D, Issekutz TB (2003) Identification of tissue transglutaminase as a novel molecule involved in human CD8+ T cell transendothelial migration. J Immunol 171:3179–3186PubMedGoogle Scholar
  46. Nakaoka H, Perez DM, Baek KJ et al (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264:1593–1596PubMedCrossRefGoogle Scholar
  47. Nanda N, Iismaa SE, Dagger Owens WA, Husain A, Mackay F, Graham RM (2001) Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 276:20673–20678PubMedCrossRefGoogle Scholar
  48. Nicholas B, Smerthurst P, Verderio E, Jones R, Griffin M (2003) Crosslinking of cellular proteins by tissue transglutaminase during necrotic cell death: mechanism for maintaining tissue integrity. Biochem J 371:413–422PubMedCrossRefGoogle Scholar
  49. Nimwegen MJ, Water B (2007) Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73:597–609PubMedCrossRefGoogle Scholar
  50. Owens LV et al (1995) Overexpression of the focal adhesion kinase in invasive human tumors. Cancer Res 55:2752–2755PubMedGoogle Scholar
  51. Priglinger SG, Alge CS, Neubauer AS, Kristin N et al (2004) TGFb-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. Invest Ophthalmol Vis Sci 45:955–963PubMedCrossRefGoogle Scholar
  52. Rodolfo C, Mormone E, Matarrese P et al (2004) Tissue transglutaminase is a multifunctional BH-3-only protein. J Biol Chem 279:54783–54792PubMedCrossRefGoogle Scholar
  53. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D (2007) Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 67:7194–7202PubMedCrossRefGoogle Scholar
  54. Sawai H, Okada Y, Funahashi H et al (2005) Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via ERK-1/2 signaling pathway activation. Mol Cancer 4:37–44PubMedCrossRefGoogle Scholar
  55. Schlaepfer DD, Hauck CR, Sieg DJ (1999) Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71:435–478PubMedCrossRefGoogle Scholar
  56. Tanida I, Ikeguchi NM, Ueno T, Kominami E (2005) Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1:84–91PubMedGoogle Scholar
  57. Verderio EAM, Johnson TS, Griffin M (2005) Transglutaminases in wound healing and inflammation. Prog Exp Tumor Res 38:89–114PubMedCrossRefGoogle Scholar
  58. Verma A, Mehta K (2007a) Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10:144–151PubMedCrossRefGoogle Scholar
  59. Verma A, Mehta K (2007b) Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7:559–565PubMedCrossRefGoogle Scholar
  60. Verma A, Wang H, Manavathi B et al (2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66:10525–10533PubMedCrossRefGoogle Scholar
  61. Verma A, Guha S, Fok JY et al (2008a) Tissue transglutaminase regulates FAK/Akt activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 14:1997–2005PubMedCrossRefGoogle Scholar
  62. Verma A, Guha S, Diagaradjane P et al (2008b) Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14:2476–2483PubMedCrossRefGoogle Scholar
  63. Weiner TM, Liu ET, Craven RJ, Chance WJ (1993) Expression of focal adhesion kinase gene and invasive cancer. Lancet 342:1024–1025PubMedCrossRefGoogle Scholar
  64. Xu L, Begum S, Hearn JD, Hynes RO (2006) GPR56, an atypical G protein-coupled receptor, bind tissue transglutaminase and inhibits melanoma tumor growthand metastasis. Proc Natl Acad Sci 103:9023–9028PubMedCrossRefGoogle Scholar
  65. Yamaguchi H, Wang HG (2006) Tissue transglutaminase serves as an inhibitor of apoptosis by cross linking caspase 3 in thapsgargin-treated cells. Mol Cell Biol 26:569–579PubMedCrossRefGoogle Scholar
  66. Yu L, Lenardo MJ, Baehrecke EH (2004) Autophagy and caspases: a new cell death program. Cell Cycle 3:1124–6PubMedGoogle Scholar
  67. Yuan L, Siegel M, Choi K et al (2006) Transglutaminase 2 inhibitor, KCC009 disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26:2563–2573PubMedCrossRefGoogle Scholar
  68. Zemskov EA, Janiak A, Hang J, Waghray A, Belkin AM (2006) Role of tissue transglutaminase in cell–matrix interactions. Front Biosci 11:1057–1076PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Experimental TherapeuticsThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations